Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, MCM Cheung, AJ Walker… - Journal of …, 2016 - Elsevier
Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …
被引用次数：584 相关文章
[PDF] qmul.ac.uk

[PDF][PDF] Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, MCM Cheung… - JOURNAL OF …, 2016 - qmro.qmul.ac.uk
Methods Patients with HCV and decompensated cirrhosis or at risk of irreversible disease
were treated in an Expanded Access Programme (EAP) in 2014. Treatment, by clinician …

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, M Cheung… - Journal of … - nottingham-repository.worktribe.com
© 2016 European Association for the Study of the Liver. Background & Aims All oral direct
acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the …

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

GR Foster, WL Irving, MC Cheung, AJ Walker… - Journal of …, 2016 - europepmc.org
Methods Patients with HCV and decompensated cirrhosis or at risk of irreversible disease
were treated in an expanded access programme (EAP) in 2014. Treatment, by clinician …
[PDF] natap.org

[PDF][PDF] Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, MCM Cheung, AJ Walker… - 2016 - natap.org
Background & Aims: All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis
C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We …

Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, M Cheung, AJ Walker… - Journal of …, 2016 - eprints.gla.ac.uk
Background & Aims: All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis
C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We …

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, MCM Cheung… - Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Background & aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …
[PDF] core.ac.uk

[PDF][PDF] Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

GR Foster, WL Irving, MC Cheung, AJ Walker… - 2016 - core.ac.uk
Methods Patients with HCV and decompensated cirrhosis or at risk of irreversible disease
were treated in an Expanded Access Programme (EAP) in 2014. Treatment, by clinician …

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, MCM Cheung, AJ Walker… - Journal of …, 2016 - infona.pl
All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV)
infection, but the benefits in advanced liver disease are unclear. We compared outcomes in …

Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

GR Foster, WL Irving, MCM Cheung… - Journal of …, 2016 - research.birmingham.ac.uk
BACKGROUND AND AIMS: All oral direct-acting antivirals (DAAs) effectively treat chronic
hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We …